Potential Class Action Lawsuit Against Vistagen Therapeutics: A Call to Investors

Opportunity to Join Vistagen Therapeutics Securities Class Action

Investors in Vistagen Therapeutics, Inc. have a critical opportunity to join a potential class action lawsuit, aimed at addressing substantial allegations of securities fraud. The Schall Law Firm, which specializes in litigation focused on shareholder rights, has reminded investors of their ability to participate in this legal endeavor.

Background of the Case

The allegations against Vistagen Therapeutics stem from problematic claims made during the company's Class Period, which spans from April 1, 2024, to December 16, 2025. The firm asserts that Vistagen allegedly made misleading statements regarding the viability of its fasedienol drug candidate. These statements led investors to believe that Vistagen was likely to experience success in its Phase 3 clinical trial, specifically the PALISADE-2 trial, even though there were significant risks that were downplayed.

Misleading Information and Investor Loss

At the crux of the matter is the assertion that Vistagen provided a false picture to the market, which ultimately resulted in significant financial losses for investors. The company's claims regarding its drug candidate's prospects were allegedly unfounded, resulting in misleading public statements throughout the specified class period. Once the market became aware of the actual situation, investors began to suffer damages as a result of their reliance on the company's inaccurate representations.

Legal Representation and Next Steps

Individuals who purchased Vistagen's securities during the specified period and suffered losses are encouraged to reach out to the Schall Law Firm before the upcoming deadline of March 16, 2026, to explore their rights and potential involvement in this class action. Contacting Brian Schall, an attorney from the firm, will enable shareholders to receive consultations at no charge regarding their participation options. For those interested, further details can be accessed through the Schall Law Firm's website or by calling their office directly.

Important Information for Investors

It's essential to note that the class in this lawsuit has yet to be certified, which means that until certification occurs, investors who do not take action may remain unrepresented in this legal proceeding. Choosing to take no steps may lead to a lack of recourse as an absent class member. However, actively joining the class gives potential for collective recovery of losses suffered during the period.

Conclusion

The events surrounding Vistagen Therapeutics highlight significant concerns regarding corporate transparency and shareholder rights. Investors are urged to carefully consider their options and the implications of the allegations made against the company. The Schall Law Firm stands ready to assist those impacted by the alleged misconduct. By providing this information, the firm aims to empower investors with knowledge and legal support as they navigate this challenging situation.

For more perspective on these legal matters or to discuss rights concerning this case, investors should not hesitate to contact the Schall Law Firm for further assistance and guidance.